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BACKGROUND: The United Kingdom NHS Breast Screening Programme was established in 1988, and women aged between 50 and 70
are routinely invited at three yearly intervals. Expected United Kingdom interval cancer rates have been calculated previously, but this
is the first publication from an exercise to collate individual-based interval cancer data at a national level.
METHODS: Interval cancer case ascertainment is achieved by the regular exchange of data between Regional Breast Screening Quality
Assurance Reference Centres and Cancer Registries. The present analysis includes interval cancers identified in women screened
between 1st April 1997 and 31st March 2003, who were aged between 50 and 64 at the time of their last routine screen.
RESULTS: In the periods40–o12 months, 12–o24 months and 24–o36 months after a negative screen, we found overall interval
cancer rates and regional ranges of 0.55 (0.43–0.76), 1.13 (0.92–1.47) and 1.22 (0.93–1.57) per 1000 women screened,
respectively. Rates in the period 33–o36 months showed a decline, possibly associated with early re-screening or delayed
presentation.
CONCLUSIONS: Interval cancer rates were higher than the expected rates in the 24-month period after a negative screen, but were
similar to published results from other countries. Increases in background incidence may mean that the expected rates are
underestimated. It is also possible that, as a result of incomplete case ascertainment, interval cancers rates were underestimated in
some regions in which rates were less than the expected.
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The main aim of a breast cancer screening programme is to reduce
breast cancer mortality by detecting (and treating) cases of
the disease at an earlier stage than that at which they would have
presented clinically. A proportion of cancers will occur between
scheduled screening episodes and these are termed interval
cancers (Bulliard et al, 2006). These can include cases missed at
the previous screen, cancers not visible by mammography and
cases becoming both mammographically detectable and sympto-
matic after the screen (Warren and Duffy, 2000). Interval cancer
rates can provide information on the sensitivity of the screening
test, the natural history of the disease and on appropriate
screening intervals, and they will also be affected by trends in
background incidence.
Breast cancer screening was introduced in the United Kingdom
in 1988 and women are invited at three yearly intervals. Initially
the 50–64 age group was invited to screening, but more recently
invitation has been extended to include women up to age 70
(Bennett et al, 2009). Monitoring and evaluation of the National
Health Service Breast Screening Programme (NHSBSP) has been
integral since it began (Chamberlain et al, 1993; Moss et al, 1995;
Blanks et al, 2000; Bennett et al, 2007), and aggregated screening
activity and outcome data are reported annually (The NHS
Information Centre, 2010).
National data on interval cancers have not been available in the
past and consequently estimates of interval cancer rates in the
NHSBSP have relied on the publication of regional data. In 1995,
rates of 1.8 and 1.9 per 1000 women screened for the periods
0–o24 and the 24–o36 months after a negative screen,
respectively, were reported in East Anglia and 1.6 and 1.5 per
1000 women screened, respectively, in the North West region (Day
et al, 1995; Woodman et al, 1995).
The present descriptive study reports the initial results from an
on-going project to collate individual-based interval cancer data at
a national level. This was a collaborative exercise involving the
Cancer Screening Evaluation Unit (CSEU), the NHS Cancer
Screening Programme, Regional Breast Screening Quality Assur-
ance Reference Centres (QARCs) and Regional Cancer Registries.
METHODS
NHS breast screening programme in England, Wales and
Northern Ireland
On average 1 574 554 women per year were routinely invited for
screening between 1997/98 and 2002/03. Average uptake was 68%
at prevalent screens and 86% at incident screens. During this
period two-view mammography was used at all prevalent screens,
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and also at incident screens in Northern Ireland. Two-view
mammography at the incident screen was introduced in Wales
in 2001 and units in England were expected to have performed so
by 2003 (Bennett et al, 2007). The majority of mammograms were
double read, and rates of recall for assessment were 8.1 and 3.9% at
prevalent and incident screens, respectively. Further assessment
can include clinical examination, further imaging and biopsy.
Interval cancers in the NHSBSP: standards and
ascertainment
In 2008, the United Kingdom NHSBSP was delivered at a local level
by 92 individual screening services. Standards, including those for
interval cancers, exist across all professional groups involved in
delivering the service. At a regional level, representatives of each of
these professional groups join together to form quality assurance
teams, whose role is to ensure that standards are being met by
their local screening services. Quality Assurance Reference Centres
act to support the team and have a considerable role in the
regional collation, processing and monitoring of screening activity
data including interval cancers. Expected United Kingdom interval
cancer rates have been previously calculated as 0.45, 0.65 and 1.30
per 1000 women screened for the three 12-month periods after a
negative screen (Moss and Blanks, 1998). These were based on
rates reported from the Swedish Two-County Study, but were
adjusted for the background incidence rate of breast cancer in
England and Wales in 1980–1987, extrapolated to 1995. All these
rates were based on invasive cancers only.
Ensuring good ascertainment is labour intensive as a regular
search of possible sources must be undertaken in order to identify
the screen (and assessment) negative women who subsequently
develop an interval cancer, as they may not present symptoma-
tically at their local screening unit. Regional Cancer Registries are
ideally placed to assist the screening programme in identifying
interval cancers, as they are responsible for actively collecting data
on all cancers occurring in their region and their registration is
based on multiple sources. Collaboration between QARCs and
Cancer Registries allows the two-way exchange of data relating to
all breast cancers in a region’s target population. In England,
regional QARCs are required to have a service level agreement
(SLA) with their Regional Cancer Registry and are responsible for
linking cancer registry and screening data, as well as assigning a
screening classification to all breast cancer cases in order that
interval cancers can be identified (NHS Cancer Screening
Programmes, 2007).
Interval cancers in the NHSBSP: definition
The definition of interval cancers in the NHSBSP (NHS Breast
Screening Radiologists Quality Assurance Committee, 2005) is
consistent with that in the European guidelines (Perry et al, 2006);
breast cancers diagnosed in the interval between scheduled
screening episodes in women screened and given a ‘normal’
screening result that is, the previous screening episode was
negative. In our analyses we defined core interval cancers as those
occurring within 36 months of a woman’s last negative-screening
episode in women aged between 50 and 64 at their last routine
screen; only invasive cancers were included in the analysis to allow
comparison with expected United Kingdom interval cancer rates
(The age range was restricted to 50–64 as women aged between 65
and 70 were not routinely invited during the full analysis period).
The data were checked for duplicate records; women with
bilateral cancers were recorded once and the pathology informa-
tion (where available) for the cancer with the worst Nottingham
Prognostic Index score used. Contralateral cancers detected at
follow-up of screen-detected cancers were excluded. Cancers,
which were a recurrence were also excluded as these are not
generally collected by Cancer Registries; however, it is not possible
to identify recurrences detected at screening, although the number
is likely to be small (NHS Breast Screening Programme and
Association of Breast Surgery at BASO, 2010).
National collation of individual interval cancer data
Data included in this analysis related to interval cancers identified
in women last routinely screened in the 6 years between 1st April
1997 and 31st March 2003. These data have been collated as part of
a nationwide exercise, in which individual-based data are annually
requested from United Kingdom regions and countries by the
CSEU for interval cancers occurring in a defined cohort of
women, for example, all interval cancers in women routinely
screened between 1 April 2002 and 31 March 2003. The NHSBSP is
exempt from obtaining individual consent under section 60 of the
Health and Social Care Act 2001. The minimum data set included
information on screening unit, dates of birth, last routine screen
and breast cancer diagnosis and invasive status of the cancer.
Information on previous screening history and tumour histology
was also requested, but these data were not complete enough to
include in this analysis.
Analysis
Interval cancer rates were calculated per 1000 women screened.
Data on numbers of women screened were available from routinely
collected data (KC62 return) and included all routine screens,
but not short-term recalls. Rates of interval cancers and screen-
detected cancers (including the Standardised Detection Ratio
(SDR) measure) (Blanks et al, 1996) were calculated at both a
national and regional level for each screening year and 5-year-age
group, and additionally for interval cancers by the time since last
screen.
There have been several regional boundary changes during the
analysis period. We have therefore, assumed the configuration of
regions and their responsibility for individual units to be that as in
2008. For each region, we ensured that their data included all the
screening units for which they had responsibility, and that they
had submitted data for each of the 6 screening years.
RESULTS
Identification of core interval cancers
Data on 26 475 interval cancers occurring in women routinely
screened in the 6 years between 1 April 1997 and 31 March 2003 were
collected from all English QARCs and from Wales and Northern
Ireland. Data for Scotland were not available for inclusion.
A total of 66 cases were excluded because of missing or invalid
data; for 60 cases we could not calculate either the age of a woman
at her last routine screen or the time from this screen to her
diagnosis of cancer, and for six cases the date of last routine screen
was either equal to or greater than the date of diagnosis. The
invasive status was known for 25 657 (97.15%) of the remaining
cases (regional range, 90.78–100%). Figure 1 shows the overall
breakdown of cases by invasive status, age group and time since
last screen. The invasive status of 1180 (4.60%) of cases was
reported as either in-situ or micro-invasive. Of the 24 477 invasive
interval cancers, 22 042 (90.05%) occurred in women aged between
50 and 64 at their last routine screen, and 21 281 of these cases
(96.55%) were diagnosed within 36 months of the woman’s last
screen.
Interval cancer rates
Table 1 shows the interval cancer rates in each of the 6 screening
years, and the observed regional range. The interval cancer rate
over the 6-year period was 2.91 per 1000 women screened (regional
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range, 2.28–3.79 per 1000 women screened). Overall rates
increased during the analysis period from 2.65 per 1000 women
screened in 1997/98 to a peak of 3.18 per 1000 women screened in
2000/01 and decreased in the final 2 screening years. The rate of
interval cancers in the period 40–o12 months after a negative
screen was 0.55 per 1000 women screened and was similar in each
of the 6 screening years. The rates of interval cancers were similar
in the periods 12–o24 and 24–o26 months after a negative
screen (1.13 per 1000 women screened and 1.22 per 1000 women
screened, respectively). We would expect the rates of interval
cancers to increase with time since last screen. However, as rates in
the period 24–o36 months after a negative screen were similar to
those in the period 12–o24 months we examined the distribu-
tion of rates in the 24–o36 months period (Figure 2). There
was a decrease in rates in the period 33–35 months mainly in
the 50–54 and 55–59 age groups. This may be a result of some
breast-screening units re-screening women less than 36 months
since their last routine screen, or because women with symptoms
have waited for their invitation to screening rather than presenting
symptomatically. Rates of interval cancers are similar in the age
groups 50–54, 55–59 and 60–64 both overall and by the time
since last screen (Table 2).
Screen-detected cancers
During the 6-year period from 1st April 1997 to 31st March 2003
there was an increase in the rate of screen-detected cancers, for
invasive cancers from 4.17 to 5.32 per 1000 women screened and
for non-invasive cancers from 1.17 to 1.46 per 1000 women
screened (Table 3). Over the same time period, invasive cancer
detection rates for the 50–54, 55–59 and 60–64 age groups were
4.21, 4.52 and 5.68 per 1000 women screened, respectively
Micro-invasive 
82
(0.31%)
Invasive
24 477
(92.45%)
Number of records with known (and valid) 
dates of birth, last routine screen and 
diagnosis and known invasive status 
25 657 
(96.91%) 
Total number of eligible records 
26 475
In-situ 
1098
(4.15%)
65 years
1751
(6.61%)
< 50 years
684
(2.58%)
50–64 years
22 042
(83.26%)
24 – < 36 months
8944
(33.78%)
> 0 – <12 months
 4048
(15.29%)
12 – < 24 months 
8289
(31.31%)
36 months 
761
(2.87%) 
>0 – < 36 months 
21 281
(80.38%)
Invasive status 
of cancer
Age at last routine
 screen
Time since last 
routine screen
Figure 1 Flowchart showing breakdown of total cases by invasive status, age at last routine screen and time since last screen.
Table 1 Breast interval cancers in women aged 50–64 at last routine screen and diagnosedo36 months since this screen, by the time since last screen
and screening year
40–o12 months X12–o 24 months X24–o36 months 40–o36 months
Interval
cancers
Interval
cancers
Interval
cancers
Interval
cancers
Year of last routine screen
Women
screened n /1000
Regional
range n /1000
Regional
range n /1000
Regional
range n /1000
Regional
range
1 April 1997–31 March 1998 1148986 555 0.48 0.17–0.71 1180 1.03 0.56–1.56 1311 1.14 0.75–1.71 3046 2.65 1.62–3.78
1 April 1998–31 March 1999 1192474 651 0.55 0.24–0.84 1284 1.08 0.71–1.42 1379 1.16 0.76–1.62 3314 2.78 1.81–3.84
1 April 1999–31 March 2000 1262681 707 0.56 0.38–0.77 1450 1.15 0.81–1.47 1597 1.26 0.69–1.74 3754 2.97 1.94–3.81
1 April 2000–31 March 2001 1247661 733 0.59 0.38–0.84 1568 1.26 0.85–1.80 1670 1.34 0.88–1.69 3971 3.18 2.34–4.29
1 April 2001–31 March 2002 1211972 711 0.59 0.35–0.84 1398 1.15 0.88–1.45 1516 1.25 0.93–1.63 3625 2.99 2.33–3.81
1 April 2002–31 March 2003 1256874 691 0.55 0.37–0.69 1409 1.12 0.78–1.45 1471 1.17 0.85–1.54 3571 2.84 2.03–3.56
Overall (1 April 1997–31 March 2003) 7320648 4048 0.55 0.43–0.76 8289 1.13 0.92–1.47 8944 1.22 0.93–1.57 21281 2.91 2.28–3.79
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(Table 4). For women aged 50–64, the non-invasive cancer
detection rate was 1.30 per 1000 women screened and was similar
in each of the three age bands.
Overall, interval cancers accounted for 32.49% of all breast
cancers diagnosed in women screened during the 6-year period
between 1st April 1997 and 31st March 2003, and the percentages
of interval cancers were 32.86%, 35.00% and 29.33% in the 50–54,
55–59 and 60–64 age groups, respectively.
Regional variation in interval cancer rates
Although there were overall increases in rates of both screen-
detected cancers and interval cancers during the analysis period,
we found little relationship between the SDR and interval cancer
rates at a regional level. Variation in regional interval cancer
rates was particularly notable in the earlier years, with more than
a two-fold difference in rates.
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Figure 2 Interval cancer rates in 24–o36-month period after a negative screen by individual month and 5-year-age group and overall.
Table 2 Breast interval cancers in women aged 50–64 at last routine screen and diagnosedo36 months since this screen, by the time since last screen
and 5-year-age band
40–o12 months X12–o24 months X24–o36 months 40–o36 months
Interval cancers Interval cancers Interval cancers Interval cancers
Age at last
routine screen
Women
screened n /1000
Regional
range n /1000
Regional
range n /1000
Regional
range n /1000
Regional
range
50–54 2898834 1578 0.54 0.41–0.73 3065 1.06 0.89–1.41 3289 1.13 0.86–1.49 7932 2.74 2.19–3.63
55–59 2426195 1420 0.59 0.42–0.79 2996 1.23 0.94–1.50 3096 1.28 0.90–1.75 7512 3.10 2.30–3.86
60–64 1995619 1050 0.53 0.35–0.76 2228 1.12 0.88–1.51 2559 1.28 0.98–1.66 5837 2.92 2.27–3.93
50–64 7320648 4048 0.55 0.43–0.76 8289 1.13 0.92–1.47 8944 1.22 0.93–1.57 21281 2.91 2.28–3.79
Table 3 Screen-detected breast cancers (invasive and non-invasive) in women aged 50–64, by screening year
All cancer Invasivea Non-invasivea
Year of screen
Women
screened n /1000
Regional
range n /1000
Regional
range n /1000
Regional
range
1 April 1997–31 March 1998 1148986 6189 5.39 4.85–6.05 4673 4.17 3.87–4.55 1316 1.17 0.78–1.48
1 April 1998–31 March 1999 1192474 6823 5.72 4.71–6.14 5400 4.53 3.84–4.91 1376 1.15 0.69–1.38
1 April 1999–31 March 2000 1262681 7400 5.86 5.29–6.43 5752 4.56 4.30–5.11 1604 1.27 0.90–1.55
1 April 2000–31 March 2001 1247661 7574 6.07 5.51–6.47 5919 4.74 4.50–5.31 1624 1.30 1.00–1.59
1 April 2001–31 March 2002 1211972 7681 6.34 5.72–7.66 5942 4.90 4.52–6.06 1707 1.41 1.11–1.62
1 April 2002–31 March 2003 1256874 8552 6.80 6.15–7.69 6683 5.32 4.88–6.16 1837 1.46 1.15–1.66
Overall (1 April 1997–31 March 2003) 7320648 44219 6.04 5.43–6.54 34369 4.71 4.43–5.10 9464 1.30 0.98–1.44
aData not available for Northern Ireland, 1 April 1997–31 March 1998.
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As some QARCs did not routinely exchange data with their
Regional Cancer Registries in these earlier years, the lower rates
in some regions were likely to reflect poor case ascertainment.
To investigate this we compared regional interval cancer rates
in the first and last years of the analysis period (Figure 3).
The median interval cancer rate was 3.0 per 1000 women screened
in both 1997/98 and 2002/03. Rates were similar in both years in
eight regions (of which two had rates less than the median in both
years), and three further regions had significantly lower rates in
the first year than in the last year of the analysis period.
DISCUSSION
This is the first time that national data on interval cancer rates for
England, Wales and Northern Ireland have been published. This
analysis has presented interval cancers in women screened by the
NHSBSP for the period 1997/98–2002/03. Since the programme
began, its performance (as measured by rates of screen-detected
cancers) has improved and we would therefore expect interval
cancer rates to now be lower than earlier regional estimates. In the
absence of trends in background incidence, greater sensitivity
will result in higher cancer detection rates at screening and lower
interval cancer rates. Both rates will increase with increasing
background incidence. We showed that rates of screen-detected
cancers increased up to 2002/03, and rates of interval cancers
increased up to 2000/01 but declined slightly between 2001/02
and 2002/03 possibly because of the introduction of two-view
mammography at incident screens (Lawrence et al, 2009).
However, even in these later years overall interval cancer rates
were still higher than those expected. This may reflect an increase
in the background incidence rate, partly as a result of hormone
replacement therapy (HRT) use (Advisory Committee on Breast
Cancer Screening, 2006). It has been estimated that there has been
an 11% increase in background incidence since the expected
interval cancer rates were calculated (Waller et al, 2007). Allowing
for this increase, the expected interval cancer rates would be
0.50, 0.72 and 1.44 per 1000 women screened for each of the
three 12-month periods after a negative screen. Further, the SDR
(which compares observed cancers with those expected based on
the Swedish Two-County Study, and is adjusted for background
incidence) would be reduced; in 2003, from 1.32 to 1.19
(Bennett et al, 2007). The use of HRT has decreased in more
recent years (Watson et al, 2007) and this will result in further
changes in the background incidence rate that need to be taken
into account.
In the period40–o24 months after a negative screen observed
interval cancer rates were higher than the expected rates, but rates
in the period 24–o36 months were similar to those expected.
There was a decline in rates in the period 33–35 months which
may be associated with either delayed symptomatic presentation
because of anticipated screening invitations, or with early
re-screening. It is recommended that individual screening services
plan a 34-month screening round in order that women are
re-screened within 36 months (J Patnick, personal communica-
tion). A similar trend before re-screening was also observed in
the Norwegian screening programme (Wang et al, 2001). Equally,
round length slippage results in some interval cancers occurring
more than 36 months after a woman’s last screen and may inflate
rates of screen-detected cancers. Linking screening service and
cancer registry data to enable individual follow-up to be estimated
allows interval cancer rates to be calculated per woman years
instead of per women screened and takes account of early
re-screening/round length slippage and loss to follow-up; however
this process is labour intensive (Fracheboud et al, 1999).
International comparisons of interval cancers are difficult,
as many differences may exist between countries. Background
incidence, the definition of an interval cancer, the quality of case
ascertainment and the delivery of the programme (e.g., recall to
assessment rate, two-view mammography and double reading of
mammograms) will all be reflected in reported interval cancer
rates. Despite similarities in many of these factors, a recent study
of six European countries showed interval cancer rates ranging
from 0.8 to 2.1 per 1000 women screened in the 24-months period
following screening, for women aged 50–69 years (Tornberg et al,
2010). These results included cases of DCIS, and the average rate
of 1.9 per 1000 women screened was similar to results from
our analyses for women aged 50–64, if these cases were included
(1.8 and 1.3 per 1000 women screened for the periods 0–o24 and
24–o36 months after a negative screen), and to results published
by the Netherlands and Norway (both 1.8 per 1000 women
screened for women aged 50–69) (Fracheboud et al, 1999; Hofvind
et al, 2009). The rate for invasive cancers only in Norway for the
Table 4 Screen-detected breast cancers (invasive and non-invasive) in women aged 50–64, by 5-year-age band
All cancer Invasivea Non-invasivea
Age at screen Women screened n /1000 Regional range n /1000 Regional range n /1000 Regional range
50–54 2898834 16207 5.59 4.97–6.08 12157 4.21 3.97–4.64 3929 1.36 1.00–1.52
55–59 2426195 13951 5.75 5.26–6.07 10924 4.52 4.20–4.75 2898 1.20 0.87–1.42
60–64 1995619 14061 7.05 6.33–7.79 11288 5.68 5.18–6.41 2637 1.33 1.09–1.52
Overall 50–64 7320648 44219 6.04 5.43–6.54 34369 4.71 4.43–5.10 9464 1.30 0.98–1.44
aData not available for Northern Ireland, 1 April 1997–31 March 1998.
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Figure 3 Regional interval cancer rates with 90% confidence intervals,
screening years 1997/98 and 2002/03.
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period 0–o24 months after a negative screen was 1.7 per 1000,
similar to that reported in our study. Cases of DCIS are unlikely to
present symptomatically and those occurring in the interval
between scheduled screening episodes are likely to reflect screen-
ing outside of organised programmes (Bulliard et al, 2006). In this
analysis less than 5% of cancers occurring in the 36-months period
after a negative screen were non-invasive, whereas non-invasive
cancers accounted for 21.40% of the 21 281 screen-detected cases.
Overall interval cancers accounted for approximately one third of
all cancers in women screened in the period 1997/98–2002/03.
However, measures to reduce interval cancer rates for example by
aiming to maximise screened detection rates may result in higher
rates of false positives, whereas reducing the screening interval
would result in a lower proportion of interval cancers, but not
necessarily a significantly greater mortality reduction (Duffy and
Blamey, 2008).
The variation in regional interval cancer rates suggests that
interval cancer rates reported in this analysis may be under-
estimated in some regions. Although there has been much
standardisation in regional methods of interval cancer case
ascertainment, this variation may reflect continuing timeliness
issues and differences in ascertainment, both in terms of cancer
registration and exchanges between the Regional Cancer Registries
and QARCs. This project has involved a considerable amount of
work for some QARCs that previously had not routinely exchanged
data with their Regional Cancer Registry, and although cancer
registration in the United Kingdom is not statutory (and may be
incomplete compared with European countries with statutory
registration (Beral and Peto, 2010)), regular data exchange remains
the best way of ensuring high ascertainment of interval cancers.
Regional differences in data exchange between QARCs and
Cancer Registries have been suggested in annual reports from
the United Kingdom Association of Cancer Registries (United
Kingdom Association of Cancer Registries, 2009), and in results
from the Breast Cancer Clinical Outcome Measures (BCCOM)
project (Bates et al, 2009). Regions with higher interval cancer rates,
such as the West Midlands, tend to have both a Cancer Registry
with high levels of estimated completeness and well-established
routine data exchange between the QARC and the Cancer Registry
(Lawrence et al, 2009), and rates in these regions are likely to reflect
true interval cancer rates. The exchange of data between QARCs
is also expected to ensure that interval cancers are picked up in
women who have moved or been treated in a different region.
The regions with rates lower than the median in both the first
and last years of the analysis period reported having improved
their links with their Cancer Registries during the analysis period
but believed their data for 2002/03 to be incomplete, as some
potential interval cancer cases were still awaiting validation/
verification at the time of data submission. The region with a lower
interval cancer rate in 2002/03 than in 1997/98 was unable to
provide the invasive status of 25% of cancers in eligible women for
the latest screening year, and consequently, these cancers were not
included in the analyses. The three regions with rates lower in the
earliest year than the latest year reported a number of reasons why
these earlier rates may be underestimated including incomplete
data exchange with their Regional Cancer Registry at the time of
data submission to CSEU.
As a result of the different regional workloads associated with
the collection of these data at a regional level, this exercise
concentrated only on a few key variables such as invasive status
and dates of birth, last routine screen and diagnosis. Information
on previous screening history and tumour histology was also
requested but the available data were not complete enough to be
included in this paper. As the routine collection of data on interval
cancers is now established in all QARCs, future work should aim to
collect all of these data routinely, thus allowing interval cancers
rates to be examined in more detail, for example by comparing the
pathology characteristics of interval cancers with those of screen-
detected cancers. We have shown that interval cancers rates are
higher than expected in the first 2 years after screening, and
further longitudinal analyses will allow trends in rates of interval
cancers to be examined.
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